LOTTE Biologics
About LOTTE Biologics
Certifications
-
FDA -
GMP
Categories
-
KR -
2022On CPHI since
-
3Certificates
-
500 - 999Employees
Company types
Contact info
-
-
-
300 Olymoic-ro, Songpa-gu, 05551, Seoul, Seoul, Korea, Republic Of
LOTTE Biologics Resources (1)
-
Brochure LOTTE BIOLOGICS Brochure
Headquartered in Seoul, South Korea, LOTTE BIOLOGICS was founded in 2022 with a mission to contribute to a healthier world through innovative therapies. At the Syracuse Bio Campus in New York, it offers high-quality GMP manufacturing services for drug substances, with a capacity of 40,000L supported by eight 5,000L stainless steel bioreactors. The facility includes QC testing laboratories and warehouses approved by over 62 global regulatory agencies. By early 2025, LOTTE BIOLOGICS will expand into Antibody-Drug Conjugates (ADCs) conjugation services, with over $80 million invested in ADC capabilities for seamless end-to-end services.
By 2030, LOTTE BIOLOGICS is constructing three bio plants in Songdo, South Korea. The first plant, operational by 2026, will feature eight 15,000L bioreactors for commercial production and multiple 2,000L bioreactors for clinical production. Together, these facilities will offer over 360,000L of manufacturing capacity.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance